Showing 1 - 20 results of 106 for search '"Melanoma drug therapy"', query time: 1.27s Refine Results
1

Source: BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144

File Description: application/pdf

HTML Full Text     PDF Full Text
2

Source: International Journal of Molecular Sciences, Vol 21, Iss 8021, p 8021 (2020)
International Journal of Molecular Sciences
International journal of molecular sciences, vol. 21, no. 21, pp. E8021
Volume 21
Issue 21

File Description: application/pdf

3

Source: Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for Immunotherapy of Cancer

File Description: application/pdf

4

Source: International Journal of Molecular Sciences
Volume 20
Issue 18
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4484 (2019)
Molnár, E, Garay, T, Donia, M, Baranyi, M, Rittler, D, Berger, W, Tímár, J, Grusch, M & Hegedűs, B 2019, ' Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma : Increased Cell Migration and Its Association with EGFR Expression ', International Journal of Molecular Sciences, vol. 20, no. 18, 4484 . https://doi.org/10.3390/ijms20184484

File Description: application/pdf

HTML Full Text     PDF Full Text
5

Source: Castiello, L, Zevini, A, Vulpis, E, Muscolini, M, Ferrari, M, Palermo, E, Peruzzi, G, Krapp, C, Jakobsen, M, Olagnier, D, Zingoni, A, Santoni, A & Hiscott, J 2019, ' An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation ', Cancer Immunology, Immunotherapy, vol. 68, no. 9, pp. 1479-1492 . https://doi.org/10.1007/s00262-019-02380-2

7

Source: Oncotarget
Bjoern, J, Lyngaa, R, Andersen, R, Rosenkrantz, L H, Hadrup, S R, Donia, M & Svane, I M 2017, ' Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma ', OncoTarget, vol. 8, no. 16, pp. 27062-27074 . https://doi.org/10.18632/oncotarget.16003
Bjørn, J, Lyngaa, R B, Andersen, R, Rosenkrantz, L H, Hadrup, S R, Donia, M & Svane, I M 2017, ' Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma ', OncoTarget, vol. 8, no. 16, pp. 27062-27074 . https://doi.org/10.18632/oncotarget.16003

File Description: application/pdf

8
9

Contributors: Immunologie humaine, physiopathologie & immunithérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre de Diagnostic et de Thérapeutique, Hôpital de l’Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Cytogénétique Constitutionnelle [Hospices civils de Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Bordeaux [Bordeaux], Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Hôpital Ambroise Paré [AP-HP], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital Morvan - CHRU de Brest (CHU - BREST ), Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Centre hospitalier universitaire de Nantes (CHU Nantes), Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP)

Source: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 112, pp.38-46. ⟨10.1016/j.ejca.2019.02.009⟩

10

Source: Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 50
Fässler, Mirjam; Diem, Stefan; Mangana, Joanna; Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Ring, Sandra; Niederer, Rebekka; Del Carmen Gil Cruz, Cristina; Pérez Shibayama, Christian Ivan; Krolik, Michal; Siano, Marco; Joerger, Markus; Recher, Mike; Risch, Lorenz; Güsewell, Sabine; Risch, Martin; Speiser, Daniel E; Ludewig, Burkhard; Levesque, Mitchell P; Dummer, Reinhard; Flatz, Lukas (2019). Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal for ImmunoTherapy of Cancer, 7:50.
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer

File Description: application/pdf

11

Source: Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
Journal of Clinical Oncology

File Description: application/pdf

13

Source: Meng, Y, Hertel, N, Ellis, J, Morais, E, Johnson, H, Philips, Z, Roskell, N, Walker, A & Lee, D 2018, ' The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ', The European Journal of Health Economics, vol. 19, no. 8, pp. 1163-1172 . https://doi.org/10.1007/s10198-018-0964-4

File Description: application/pdf

15

Source: Falk, H, Matthiessen, L W, Wooler, G & Gehl, J 2018, ' Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy ', Acta Oncologica, vol. 57, no. 3, pp. 311-319 . https://doi.org/10.1080/0284186X.2017.1355109

File Description: application/pdf

16

Source: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, 5(1):83. BMC
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)

File Description: application/pdf

17

Source: Melanoma research, vol. 27, no. 4, pp. 358-368
Mangana, Joanna; Cheng, Phil F; Kaufmann, Corina; Amann, Valerie C; Frauchiger, Anna L; Stögner, Viola; Held, Ulrike; von Moos, Roger; Michielin, Olivier; Braun, Ralph P; Levesque, Mitchell P; Goldinger, Simone M; Dummer, Reinhard (2017). Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma research, 27(4):358-368.
Melanoma Research

File Description: application/pdf

18

Contributors: PMB medici, Hubrecht Institute for Developmental Biology and Stem Cell Research

Source: Pigment Cell and Melanoma Research, 28(3), 318. Wiley-Blackwell
Pigment cell & melanoma research, 28(3), 318-23. Blackwell Publishing Ltd
Pigment Cell & Melanoma Research, 28(3), 318-23. Wiley-Blackwell

File Description: image/pdf

19

Contributors: PMB medici

Source: Nature, 508(7494), 118-22. Nature Publishing Group

PDF Full Text
20

Contributors: Internal medicine, Public and occupational health, Pathology, Bioinformatics

Source: Cell, 173(6), 1413-1425.e14. Cell Press
Cell, 173(6), 1413

File Description: image/pdf